45 related articles for article (PubMed ID: 36260984)
41. Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
Melief CJM
Cell Rep Med; 2022 Oct; 3(10):100788. PubMed ID: 36260984
[TBL] [Abstract][Full Text] [Related]
42. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
43. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
44. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
45.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
